Analysts’ Perspective: Valeant Pharma (VRX), Ryman Hospitality (RHP), Halyard Health (HYH)

Investment Analysts at Mizuho upgraded Valeant Pharmaceuticals International Inc. (NYSE:VRX) shares from Underperform to Neutral rating while increasing their price target from $10 to $15.

Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products.

*

Brokerage Firm Citigroup upgraded Ryman Hospitality Properties Inc. (NYSE:RHP) shares from Neutral to Buy rating.

Ryman Hospitality Properties, Inc. is as a real estate investment trust, which engages in owning and operating group-oriented, destination hotel assets in urban and resort markets.

*

Halyard Health Inc. (NYSE:HYH) shares were upgraded by analysts at KeyBanc Capital Mkts from Sector Weight to Overweight rating.

Halyard Health, Inc. is a medical technology company focused on preventing infection, eliminating pain and speeding recovery for healthcare providers and their patients.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/